Use Of Tizanidine
Doctors prescribe Tizanidine with or without food.
1 Dosing Information of Tizanidine:
Once the formulation has been selected and the decision to take with or without food has been made, this regimen should not be altered. Food has complex effects on tizanidine pharmacokinetics, which differ with the different formulations. Zanaflex Capsules and Zanaflex tablets are bioequivalent to each other under fasting conditions (more than 3 hours after a meal), but not under fed conditions (within 30 minutes of a meal). These pharmacokinetic differences
may result in clinically significant differences when switching administration of tablets and capsules and when switching administration between the fed or fasted state.
These changes may result in increased adverse events, or delayed or more rapid onset of activity, depending upon the nature of the switch. For this reason, the
the prescriber should be thoroughly familiar with the changes in kinetics associated with these different conditions [see Clinical Pharmacology.
The recommended starting dose is 2 mg. Because the effect of Zanaflex peaks at approximately 1 to 2 hours post-dose and dissipates between 3 to 6 hours post-dose,
treatment can be repeated at 6 to 8-hour intervals, as needed, to a maximum of three doses in 24 hours.
Dosage can be gradually increased by 2 mg to 4 mg at each dose, with 1 to 4 days between dosage increases, until a satisfactory reduction of muscle tone is achieved.
The total daily dose should not exceed 36 mg. Single doses greater than 16 mg have not been studied.
2 Dosing in Patients with Renal Impairment:
Zanaflex should be used with caution in patients with renal insufficiency (creatinine clearance < 25 mL/min), as clearance is reduced by more than 50%. In these
patients, during titration, the individual doses should be reduced. If higher doses are required, individual doses rather than dosing frequency should be increased [see
Warnings and Precautions.
3 Dosing in Patients with Hepatic Impairment:
Zanaflex should be used with caution in patients with any hepatic impairment. In these patients, during titration, the individual doses should be reduced. If higher doses
are required, individual doses rather than dosing frequency should be increased. Monitoring of aminotransferase levels is recommended for baseline and 1 month after
maximum dose is achieved, or if hepatic injury is suspected.
4 Drug Discontinuation:
If therapy needs to be discontinued, particularly in patients who have been receiving high doses (20 mg to 36 mg daily) for long periods (9 weeks or more) or who may
be on concomitant treatment with narcotics, the dose should be decreased slowly (2 mg to 4 mg per day) to minimize the risk of withdrawal and rebound hypertension,
tachycardia, and hypertonia
powered by http://amlodipine.info/